| Bone fractures and treatments | Lifetime | 148 | ES 1 | 99.06 |
| Hemophilia Treatment and Research | Lifetime | 46 | ES 1 | 98.97 |
| Orthopaedic implants and arthroplasty | Lifetime | 310 | ES 4 | 99.01 |
| Hemostasis and retained surgical items | Lifetime | 28 | ES 2 | 98.31 |
| Total Knee Arthroplasty Outcomes | Lifetime | 320 | ES 1 | 98.90 |
| Orthopedic Infections and Treatments | Lifetime | 285 | ES 3 | 98.47 |
| Musculoskeletal synovial abnormalities and treatments | Lifetime | 113 | ES 2 | 98.42 |
| Orthopedic Surgery and Rehabilitation | Lifetime | 516 | ES 8 | 98.27 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | Lifetime | 247 | ES 7 | 98.05 |
| Blood Coagulation and Thrombosis Mechanisms | Lifetime | 361 | ES 5 | 97.65 |
| Knee injuries and reconstruction techniques | Lifetime | 419 | ES 3 | 98.00 |
| Tendon Structure and Treatment | Lifetime | 370 | ES 6 | 97.43 |
| Case Reports on Hematomas | Lifetime | 51 | ES 3 | 96.52 |
| Platelet Disorders and Treatments | Lifetime | 607 | ES 11 | 96.97 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 734 | ES 13 | 96.92 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | Lifetime | 570 | ES 11 | 95.98 |
| Elbow and Forearm Trauma Treatment | Lifetime | 652 | ES 9 | 94.47 |
| Foot and Ankle Surgery | Lifetime | 753 | ES 11 | 94.32 |
| Muscle and Compartmental Disorders | Lifetime | 408 | ES 10 | 92.94 |
| Heparin-Induced Thrombocytopenia and Thrombosis | Lifetime | 661 | ES 13 | 89.33 |
| Heterotopic Ossification and Related Conditions | Lifetime | 244 | ES 7 | 85.56 |
| Tendon Structure and Treatment | 2021-2025 | 32 | ES 2 | 97.77 |
| Orthopedic Infections and Treatments | 2021-2025 | 54 | ES 3 | 98.53 |
| Total Knee Arthroplasty Outcomes | 2021-2025 | 94 | ES 1 | 98.57 |
| Hemophilia Treatment and Research | 2021-2025 | 22 | ES 2 | 98.40 |
| Knee injuries and reconstruction techniques | 2021-2025 | 122 | ES 1 | 97.36 |
| Platelet Disorders and Treatments | 2021-2025 | 89 | ES 3 | 96.63 |
| Orthopedic Surgery and Rehabilitation | 2021-2025 | 227 | ES 3 | 95.51 |
| Orthopaedic implants and arthroplasty | 2021-2025 | 431 | ES 6 | 94.86 |
| Musculoskeletal synovial abnormalities and treatments | 2021-2025 | 60 | ES 2 | 91.53 |
| Bone fractures and treatments | 2021-2025 | 251 | ES 1 | 93.20 |
| Periodontal Regeneration and Treatments | 2021-2025 | 204 | ES 18 | 92.64 |
| Myeloproliferative Neoplasms: Diagnosis and Treatment | 2021-2025 | 327 | ES 16 | 92.38 |
| Blood Coagulation and Thrombosis Mechanisms | 2021-2025 | 125 | ES 6 | 91.40 |
| Osteoarthritis Treatment and Mechanisms | 2021-2025 | 554 | ES 3 | 90.23 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 718 | ES 15 | 87.87 |
| Hemostasis and retained surgical items | 2021-2025 | 60 | ES 1 | 84.13 |
| Foot and Ankle Surgery | 2021-2025 | 563 | ES 16 | 85.11 |
| Coagulation, Bradykinin, Polyphosphates, and Angioedema | 2021-2025 | 704 | ES 24 | 76.60 |
| Heterotopic Ossification and Related Conditions | 2021-2025 | 80 | ES 4 | 74.03 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 667 | ES 13 | 62.14 |
